RR
Highly rated in
12
conditions

Dr. Rodney P. Rocconi

USA Mitchell Cancer Institute-GYN
Mobile, AL
Highly rated in
12
conditions
Specialties:Gynecologic Oncology | Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 2 Trials
Accepts:New PatientsMedicare
Highly rated in
12
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Rodney P. Rocconi's experience treating your condition:
About Dr. Rodney P. Rocconi

Rodney Rocconi is a Gynecologic Oncologist and an Oncologist in Mobile, Alabama. Rocconi has been practicing medicine for over 23 years and is highly rated in 12 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Salpingo-Oophorectomy. He is licensed to treat patients in Alabama. Rocconi is currently accepting new patients.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Rodney P. Rocconi it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Rodney P. Rocconi accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Molina Healthcare
  •  UnitedHealthcare
  •  Magnolia Health
Call to see if your plan is accepted.
Locations
1660 Spring Hill Ave, Mobile, AL 36604
Background & Education
Graduate Institution
University Of Alabama School Of Medicine, 2000
Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in AL
Hospital Affiliations
Mobile Infirmary
USA Childrens & Womens Hospital
USA Health University Hospital
Pascagoula Hospital
Thomas Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Recruiting
Publish Date: December 06, 2022
Intervention Type: Drug, Other, Biological, Procedure
Study Drugs: AdavosertibAfatinibBinimetinibCapivasertibCopanlisibCrizotinibDabrafenibDasatinibDefactinibErdafitinibFGFR Inhibitor AZD4547IpatasertibLarotrectinibNivolumabOsimertinibPalbociclibPertuzumabPI3K-Beta Inhibitor GSK2636771SapanisertibSunitinibTaselisibTrametinibTrastuzumabUlixertinibVismodegib
Study Phase: Phase 2
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Recruiting
Publish Date: September 29, 2022
Intervention Type: Biological, Drug
Study Drugs: GEN-1CarboplatinPaclitaxel
Study Phase: Phase 1/Phase 2
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 AntibodyAGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: CarboplatinCisplatinPaclitaxel
Study Phase: Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active, not recruiting
Publish Date: September 02, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibLetrozole
Study Phase: Phase 2
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: CabozantinibPembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active, not recruiting
Publish Date: May 26, 2022
Intervention Type: Biological
Study Drug: Vigil
Study Phase: Phase 2
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Enrollment Status: Active, not recruiting
Publish Date: October 25, 2021
Intervention Type: Biological, Drug
Study Drugs: Vigil Tumor CellsAtezolizumab
Study Phase: Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 22, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes
Enrollment Status: Not yet recruiting
Publish Date: May 29, 2015
Intervention Type: Other
View 8 Less Clinical Trials -
67 Total Publications
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Journal: Communications medicine
Published: December 15, 2021
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
JS
Dr. Jennifer M. Scalici
Gynecologic Oncology | Obstetrics and Gynecology
Highly rated in
12
conditions
Gynecologic Oncology
Obstetrics and Gynecology

USA Health

USA Mitchell Cancer Institute-GYN

1660 Spring Hill Ave, 
Mobile, AL 

Jennifer Scalici is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Mobile, Alabama. Scalici has been practicing medicine for over 18 years and is highly rated in 12 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Hysterectomy. She is licensed to treat patients in Alabama and Illinois. Scalici is currently accepting new patients.

DC
Dr. Daniel G. Cameron
Oncology | Hematology Oncology
Highly rated in
59
conditions
Oncology
Hematology Oncology

Infirmary Health System

Mitchell Cancer Institute

1660 Spring Hill Ave, 
Mobile, AL 

Daniel Cameron is an Oncologist and a Hematologist Oncology expert in Mobile, Alabama. Cameron has been practicing medicine for over 25 years and is highly rated in 59 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration. He is licensed to treat patients in Alabama. Cameron is currently accepting new patients.

MF
Dr. Michael A. Finan
Gynecologic Oncology | Obstetrics and Gynecology
Highly rated in
10
conditions
Gynecologic Oncology
Obstetrics and Gynecology

Singing River Health System

Singing River Health System

2809 Denny Ave, 
Pascagoula, MS 
 34.8 mi

Michael Finan is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Pascagoula, Mississippi. Finan has been practicing medicine for over 37 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Hysterectomy, and Salpingo-Oophorectomy. He is licensed to treat patients in Mississippi and Alabama. Finan is currently accepting new patients.